- Home
- CDT vs ONFO Comparison
CDT vs ONFO Comparison
Compare CDT & ONFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDT
- ONFO
- Stock Information
- Founded
- CDT 2019
- ONFO 2018
- Country
- CDT United States
- ONFO United States
- Employees
- CDT N/A
- ONFO N/A
- Industry
- CDT Biotechnology: Pharmaceutical Preparations
- ONFO Computer Software: Programming Data Processing
- Sector
- CDT Health Care
- ONFO Technology
- Exchange
- CDT Nasdaq
- ONFO Nasdaq
- Market Cap
- CDT 5.2M
- ONFO 6.2M
- IPO Year
- CDT N/A
- ONFO 2022
- Fundamental
- Price
- CDT $0.69
- ONFO $0.91
- Analyst Decision
- CDT
- ONFO
- Analyst Count
- CDT 0
- ONFO 0
- Target Price
- CDT N/A
- ONFO N/A
- AVG Volume (30 Days)
- CDT 1.4M
- ONFO 31.1K
- Earning Date
- CDT 05-13-2025
- ONFO 05-20-2025
- Dividend Yield
- CDT N/A
- ONFO N/A
- EPS Growth
- CDT N/A
- ONFO N/A
- EPS
- CDT N/A
- ONFO N/A
- Revenue
- CDT N/A
- ONFO $6,590,171.00
- Revenue This Year
- CDT N/A
- ONFO $133.59
- Revenue Next Year
- CDT N/A
- ONFO N/A
- P/E Ratio
- CDT N/A
- ONFO N/A
- Revenue Growth
- CDT N/A
- ONFO 29.25
- 52 Week Low
- CDT $0.65
- ONFO $0.39
- 52 Week High
- CDT $350.00
- ONFO $1.88
- Technical
- Relative Strength Index (RSI)
- CDT 31.97
- ONFO 40.30
- Support Level
- CDT $0.65
- ONFO $0.61
- Resistance Level
- CDT $1.05
- ONFO $1.02
- Average True Range (ATR)
- CDT 0.14
- ONFO 0.11
- MACD
- CDT 0.07
- ONFO -0.02
- Stochastic Oscillator
- CDT 7.30
- ONFO 40.63
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.